
Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Net Margin
Oramed Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
US |
![]() |
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
|
91.5m USD |
-1 412%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
768.8B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404.9B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
180.2B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
141.2B USD |
13%
|
Oramed Pharmaceuticals Inc
Glance View
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The firm has three product pipelines: ORMD-0801 type 2, ORMD-0801 type 1 and ORMD-0901. ORMD-0801 allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, where the insulin is delivered. The company is in Phase III of clinical trials. ORMD-0901 (GLP-1 capsule), aids in the balance of blood-sugar levels and decreases appetite. The firm is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary Oravax Medical Inc., or Oravax.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Oramed Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -1 411.9%.